A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

The four anti-CD20 drugs used in the U.S. to treat relapsing MS -- ocrelizumab, ofatumumab, and ublituximab (Briumvi; ...

Roche’s Genentech unit and Repertoire Immune Medicines have entered into a partnership worth $765m to discover and develop T ...

Cancer drugs that received accelerated approval from the FDA gained regular approval significantly faster if their ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

according to the newly-released 2025 Trends in Specialty Drug Benefits Report from Pharmaceutical Strategies Group ("PSG"), ...

Patients who are immunocompromised still can receive a variety of vaccinations based on their specific needs, Cassandra ...

As the Trump administration stares down diversity programs, this big Peninsula employer is highlighting its efforts.

Genentech will pay Repertoire ... Repertoire uses that information to uncover drugs for cancer and autoimmune conditions and, so far, has publicly disclosed nine bispecific antibodies or vaccines in ...

Plans expect cell and gene therapies to pose a moderate or major financial challenge in the next two to three years, ...

Janelle Zeihen worried she'd have to file for bankruptcy after learning she owed $250,000 for her Crohn's disease treatment.